Volunteers have begun cleaning up Udu Udu lake in Boliva. Source: Reuters
Volunteers have begun cleaning up Udu Udu lake in Boliva. Source: Reuters
A couple was found dead in their bed, after a woman failed to pick up her nine-year-old son from school.
The top two based on market share are North American leader ChargePoint Holdings (NYSE: CHPT) and leading European provider EVBox, which will soon go public through a merger with SPAC TPG Pace Beneficial Finance (NYSE: TPGY). Investors haven't been able to participate in ownership of charging-station network leaders until recently. Before companies in the sector became the targets of mergers with SPACs, one popular name with investors was Blink Charging (NASDAQ: BLNK).
(Bloomberg) -- U.S. futures rose with stocks Tuesday as optimism that economic reopenings will boost growth outweighed concern about a pick-up in virus cases in parts of Asia. The dollar dipped and oil gained.Contracts on all three U.S. equity benchmarks advanced, led by those on the Nasdaq 100 Index after tech shares slid Monday. Retailers Walmart Inc. and Macy’s Inc. climbed in premarket trading after raising their full-year guidance, while Home Depot Inc. gained as its results beat estimates. Commodity and automotive shares boosted the Stoxx Europe 600 Index, while Asian equities also climbed.The dollar fell toward a four-month low, while U.S. 10-year Treasuries were steady as investors awaited key housing data ahead of minutes due Wednesday from the Federal Reserve’s last meeting. Brent crude at one point topped $70 a barrel in London for the first time since March on signs that reopenings are boosting demand.Stocks have been volatile after climbing to a record in early May as investors assessed economic growth prospects against a Covid-19 resurgence in countries including India. Traders will also parse the Fed minutes for policy discussion about inflation and hints of a timeline for reducing stimulus, after Vice Chair Richard Clarida said Monday that the weak U.S. jobs report showed the economy had not yet reached the threshold to warrant scaling back asset purchases.Global investor sentiment is “unambiguously bullish,” Bank of America Corp. strategists led by Michael Hartnett said, citing the firm’s latest fund manager survey. Inflation topped the list of the biggest tail risks, followed by a bond market taper tantrum and asset bubbles, while Covid-19 was only in fourth place.Elsewhere, Bitcoin was steady following volatility spurred by comments from Tesla Inc.’s Elon Musk. Coinbase Global Inc. fell in premarket trading after Monday’s drop below the reference price used in its April direct listing. AMC Entertainment Holdings Inc. advanced 6.9%, extending its longest rally since 2019.Here are some key events this week:The Fed publishes minutes from its April meeting Wednesday, which may provide clues to officials’ views on the recovery and how they define “transitory” when it comes to inflationEIA crude oil inventory report WednesdaySt. Louis Fed President James Bullard and Atlanta Fed President Raphael Bostic to speak at separate events WednesdayIMF Managing Director Kristalina Georgieva and ECB President Christine Lagarde speak at the Vienna Economic Dialogue ThursdayAustralia unemployment rate ThursdayEuro-area finance ministers and central bank chiefs hold an informal meeting. A larger group of EU finance ministers and central bank chiefs will meet May 22These are some of the main moves in markets:StocksFutures on the S&P 500 rose 0.2% as of 7:29 a.m. New York timeFutures on the Nasdaq 100 rose 0.5%Futures on the Dow Jones Industrial Average rose 0.1%The Stoxx Europe 600 rose 0.3%The MSCI World index rose 0.5%CurrenciesThe Bloomberg Dollar Spot Index fell 0.3%The euro rose 0.5% to $1.2209The British pound rose 0.4% to $1.4188The Japanese yen rose 0.2% to 109.02 per dollarBondsThe yield on 10-year Treasuries was little changed at 1.64%Germany’s 10-year yield was little changed at -0.12%Britain’s 10-year yield was little changed at 0.87%CommoditiesWest Texas Intermediate crude rose 0.2% to $66 a barrelGold futures were little changedMore stories like this are available on bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Clearview AI, the leading facial recognition company that provides its services to law enforcement, added 3 top professionals to its leadership team.
Bombardier Collaborates with Sterling for Enhanced Worldwide Customer Support of Parts Shipments Fully integrated solution for parts delivery further bolsters responsiveness and complements Bombardier’s extensive parts network Fully integrated solution for parts delivery further bolsters responsiveness and complements Bombardier’s extensive parts networkBombardier can now access a network of aircraft for parts dispatch to customers worldwideEnhanced parts delivery capability complements Bombardier’s rapidly growing customer service network, which is currently expanding by more than 50% MONTRÉAL, May 18, 2021 (GLOBE NEWSWIRE) -- Bombardier today announced its collaboration with Sterling Global Aviation Logistics, a global leader in aviation transportation and logistics to enhance worldwide dispatch of parts for its customers. The collaboration provides Bombardier with access to a network of aircraft, based across five continents, with which to deliver a wide variety of parts to customers quickly and efficiently in the event of an aircraft on ground (AOG) situation. “Our customers deserve fast and effortless AOG resolution and our collaboration with Sterling, an industry leader in providing AOG Logistics around the globe, allows us to quickly and efficiently deliver the parts our customers need,” said Andy Nureddin, Vice President, Customer Support, Bombardier. “We are delighted to further enhance our portfolio of solutions, and we are proud to add this offering to the ways in which we can be there for our customers when and where they need us.” “We are very excited to provide global logistics support to Bombardier’s enhanced parts delivery solutions for their customers and are proud of our long-standing strategic collaboration of over 15 years,” said Robert Broderick, Executive Vice President, Sterling Global Aviation Logistics. Bombardier customers can fly with confidence knowing that they have the backing of one of the industry’s most expansive parts distribution networks with parts facilities located across North America, Europe, Asia, and the Middle East. Shipping more than 350,000 parts annually with an impressive network-wide parts availability rate of 96%, Bombardier’s sophisticated inventory management system maximizes parts availability, shipping and tracking 24/7. Customers who buy parts from Bombardier can continue to benefit from a two-year parts warranty guarantee and price matching. The enhanced parts delivery service is one of many solutions available to customers in need of immediate assistance. Bombardier’s Mobile Response Team boasts world-class AOG coverage with 30 mobile response team trucks worldwide. Additionally, customers can count on Bombardier for support of structural repairs for its leading family of Learjet, Challenger and Global aircraft. These high-quality repair solutions are available at one single point of contact through Bombardier’s Customer Response Centre (CRC) at +1-866-538-1247 (North America) and +1-514-855-2999 (outside of North America). The cross-functional CRC teams at Bombardier are also empowered with state-of-the art tools and technology and are backed by Bombardier’s aircraft engineering expertise. Bombardier continues to reinforce its ongoing commitment to providing its customers with the most comprehensive onsite, mobile and aircraft-on-ground resolution services in the industry. This announcement is the latest in a series aimed at enhancing Bombardier’s worldwide customer service network and increasing its infrastructure footprint by 50%. These include the expansion of Bombardier’s service centre network in Berlin, Miami, Biggin Hill, London, Singapore and the new service centre to be built in Melbourne, Australia; new Line Maintenance Stations (LMS) at strategic locations in the U.S, Europe; as well as new products and services for customers, including the next steps in Bombardier’s digital transformation. About Bombardier Bombardier is a global leader in aviation, creating innovative and game-changing planes. Our products and services provide world-class experiences that set new standards in passenger comfort, energy efficiency, reliability and safety. Headquartered in Montréal, Canada, Bombardier is present in more than 12 countries including its production/engineering sites and its customer support network. The Corporation supports a worldwide fleet of approximately 4,900 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals. News and information is available at bombardier.com or follow us on Twitter @Bombardier. About Sterling Global Aviation LogisticsSince 1981, Sterling Global Aviation Logistics, a Kuehne and Nagel company, has been helping aviation clients with their worldwide priority shipping, transporting valuable aircraft parts swiftly and efficiently. Sterling specializes in shipping AOG aircraft parts, heavy weight or oversized freight, and dangerous goods, while keeping down time to a minimum. With a focus on providing global AOG Logistics, Sterling is at the forefront of innovations, offering precision, individualized service and dependability. More information is available at www.sterlingaog.aero. Bombardier, Learjet, Challenger, and Global are registered or unregistered trademark of Bombardier Inc. or its subsidiaries. For InformationMatthew NichollsBombardier +firstname.lastname@example.org For InformationMarie VigliaroloSterling Global Aviation Logistics+1-718-995-3616 ext. email@example.com A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/25b1ad57-3fc7-4617-b4fb-8d0997db07b3
Sodium Chloride Market Research Report by Grade (Rock Salt, Solar Salt, and Vacuum Salt), by Application (Chemical Production, Deicing, Feed Additive, Flavoring Agent & Food Preservative, and Pharmaceutical) - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, May 18, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Sodium Chloride Market Research Report by Grade, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05911561/?utm_source=GNW Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.1. The Global Sodium Chloride Market is expected to grow from USD 19,833.99 Million in 2020 to USD 23,874.31 Million by the end of 2025.2. The Global Sodium Chloride Market is expected to grow from EUR 17,390.82 Million in 2020 to EUR 20,933.45 Million by the end of 2025.3. The Global Sodium Chloride Market is expected to grow from GBP 15,460.47 Million in 2020 to GBP 18,609.88 Million by the end of 2025.4. The Global Sodium Chloride Market is expected to grow from JPY 2,116,789.46 Million in 2020 to JPY 2,547,994.57 Million by the end of 2025.5. The Global Sodium Chloride Market is expected to grow from AUD 28,801.59 Million in 2020 to AUD 34,668.68 Million by the end of 2025.Market Segmentation & Coverage:This research report categorizes the Sodium Chloride to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Grade, the Sodium Chloride Market studied across Rock Salt, Solar Salt, and Vacuum Salt. Based on Application, the Sodium Chloride Market studied across Chemical Production, Deicing, Feed Additive, Flavoring Agent & Food Preservative, Pharmaceutical, and Water Treatment. Based on Geography, the Sodium Chloride Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Sodium Chloride Market including Agrosal GmBH, Akzo Nobel N.V., Cargill Incorporated, Compass Minerals International Inc, Compass Minerals International, Inc., Dominion Salt Ltd, Dow Chemical Company Ltd., Gulkas Pharma Private Limited, Hebei Huachen Pharmaceutical Co., Ltd., HubPak, ICL Fertilizers, INEOS AG, K+S France S.A.S, Merck KGaA, Nouryon Holding B.V., Pon Pure Chemicals Group, SSP Pvt Limited, Swiss Salts Works AG, Südwestdeutsche Salzwerke AG, Tata Chemicals Ltd., and Wacker Chemie AG. Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Sodium Chloride Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Sodium Chloride Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Sodium Chloride Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Sodium Chloride Market?4. What is the competitive strategic window for opportunities in the Global Sodium Chloride Market?5. What are the technology trends and regulatory frameworks in the Global Sodium Chloride Market?6. What are the modes and strategic moves considered suitable for entering the Global Sodium Chloride Market?Read the full report: https://www.reportlinker.com/p05911561/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Monarch has completed a 5,286-metre (26-hole) drilling program on its wholly-owned Croinor Gold property, focused on exploration targets outside the deposit and current mineral resource envelope. High-grade mineralization intersected in the Bug Lake area includes 24.70 g/t Au over 0.6 m in hole CR-20-706 and 17.70 g/t au over 1.2 m in hole CR-20-713. Broader zones of lower-grade mineralization were intersected in the Bug Lake area, including 1.79 g/t Au over 21.0 m in hole CR-20-710 and 2.32 g/t Au over 9.6 m in hole CR-20-711. High-grade mineralization within the recently acquired Busmac claims included 16.9 g/t Au over 0.4 m intersected in hole CR-20-703. Anomalous gold mineralization was traced for several hundred metres along strike within the Croinor and Busmac horizons. Semi-massive sulphides were intersected over 7 metres in the northwest part of the property. MONTREAL, May 18, 2021 (GLOBE NEWSWIRE) -- MONARCH MINING CORPORATION (“Monarch” or the “Corporation”) (TSX: GBAR) (OTCMKTS: GBARF) is pleased to announce it has completed the exploration diamond drilling program on its wholly-owned Croinor Gold project, located 55 kilometres east of Val-d’Or, Québec. The results include several significant intersections as Monarch continues to explore this vast property covering 25 kilometres of favourable stratigraphy. The 2020-2021 diamond drilling program totalled 5,286 metres in 26 holes. It focused entirely on exploration targets outside the currently defined resource envelope of the Croinor Gold deposit. The best high-grade drill results for the Bug Lake Zone include 24.70 g/t Au over 0.6 m in hole CR-20-706 and 17.70 g/t Au over 1.2 m in hole CR-20-713, within a broader zone of 9.28 g/t Au over 3.2 m. This showing is located over 500 m east of and stratigraphically above the Croinor Gold deposit. The mineralization in hole CR-20-706 consists of visible gold hosted in quartz veins with tourmaline. Several holes drilled on the Bug Lake Zone also intersected broader zones of lower-grade gold mineralization. This includes 1.79 g/t Au over 21.0 m in hole CR-20-710 and 2.32 g/t Au over 9.6 m in hole CR-20-711. The Bug Lake Zone has currently been tested by diamond drilling over a strike length of 250 m and down to a vertical depth of approximately 250 m. Significant mineralization was intersected in the area of the Busmac showing, located 4.5 km west of and stratigraphically below the Croinor Gold deposit. Historical resources at Busmac (neither NI 43-101 compliant nor verified by Monarch’s qualified person), as reported in Sigeom (mineral deposit 32C/03-0020), include 8,200 tonnes averaging 17.5 g/t Au and a second zone of 8,000 tonnes averaging 6.8 g/t Au. Assay results from Monarch’s 2020-2021 drilling program in the area of the Busmac showing include 16.9 g/t Au over 0.4 m. Wide step-out drilling along strike of the Busmac horizon, approximately 1,000 metres to the southeast, returned 1.12 g/t Au over 4.2 m, indicating that the mineralized system is open and shows regional continuity. Hole CR-21-715, drilled in the far northwest part of the property, intersected semi-massive sulphides over a core length of 7 m. The sulphide mineralization is associated with a local magnetic high and is less than 1 km from the Realore showing (Sigeom, mineral showing 2133), which assayed up to 21.03 g/t Au and 0.76% Cu. “We are very pleased with the results of this exploration drill program, in that we have confirmed the presence of mineralization in several areas outside of the main Croinor Gold deposit,” said Jean-Marc Lacoste, President and Chief Executive Officer of Monarch. “We will continue to focus on advancing the development of the Croinor Gold deposit while at the same time exploring other showings in this vast land package covering multiple favourable horizons over more than 25 km of strike length.” Other significant results are shown in Figure 1 and Table 1, below. Figure 1: Croinor property with 2020-2021 drill results. Table 1: Significant assay results HoleFrom(m)To(m)Width*(m)Au(g/t)CR-20-697247.1248.21.13.05CR-20-698No significant assays CR-20-699180.7220.127.116.11CR-20-700275.9218.104.22.168CR-20-701115.522.214.171.124CR-20-70293.6126.96.36.199CR-20-702124.5188.8.131.52CR-20-70396.697.40.84.03CR-20-703151.9184.108.40.206CR-20-703161.4161.80.416.90CR-20-704188.3189.61.32.09CR-20-705No significant assays CR-20-70639.740.30.624.70CR-20-70758.4220.127.116.11CR-20-70861.762.71.01.44CR-20-70977.318.104.22.168CR-20-71047.768.721.01.79Including47.748.71.06.60And60.061.51.57.00And67.522.214.171.124CR-20-71128.037.69.62.32Including32.9126.96.36.199CR-20-71145.746.00.31.89CR-20-71266.767.71.01.09CR-20-712103.5105.52.05.52CR-20-71376.4188.8.131.52Including78.4184.108.40.206CR-20-71388.690.01.41.69CR-20-714No significant assays CR-20-715No significant assays CR-21-716140.0220.127.116.11CR-21-717175.8176.81.00.64CR-21-718190.218.104.22.168CR-21-71990.222.214.171.124CR-21-720136.6126.96.36.199CR-21-721No significant assays CR-21-722No significant assays *The width shown is the core length. True width is estimated at 80-85% of core length. Table 2: Drill hole location HoleEasting(UTM)Northing(UTM)Az(deg.)Dip(deg.)Length(m)CR-20-6973516635330313192-46252CR-20-6983474395330674196-47201CR-20-6993454745331433200-46300CR-20-7003458555331155200-45327CR-20-7013447345331942190-45189CR-20-7023446855331976190-45198CR-20-7033446355331992190-45183CR-20-7043447095332097190-46378CR-20-7053505085330473160-5096CR-20-7063505315330466237-5084CR-20-7073505495330473237-5090CR-20-7083505605330457237-5090CR-20-7093505575330555200-50123CR-20-7103506045330559201-50111CR-20-7113506265330365202-5269CR-20-7123506365330393200-50114CR-20-7133506365330393200-75231CR-20-7143487575328996200-45198CR-21-7153395485336449195-52432CR-21-7163494665329356209-43207CR-21-7173477675330067214-46201CR-21-7183479245330091215-45201CR-21-7193508845329919213-43204CR-21-7203510775329839210-46201CR-21-7213514925330413203-46252CR-21-7223588445327118193-50354 Sampling consists of sawing the NQ-size core into equal halves along its main axis and shipping one of the halves to the AGAT Laboratories in Mississauga, Ontario, for assaying. The samples are crushed, pulverized and assayed by fire assay, with atomic absorption finish. Results exceeding 3.0 g/t Au are re-assayed using the gravity method, and samples containing visible gold grains are assayed using the metallic screen method. Monarch uses a comprehensive QA/QC protocol, including the insertion of standards and blanks. About Croinor GoldMonarch Mining holds a 100% interest in the Croinor Gold property, which consists of one mining lease and 337 claims covering over 151.9 km2. The property includes a mineral resource estimate of 804,600 tonnes at an average grade of 9.12 g/t Au for 236,000 ounces of gold in the Measured and Indicated category, along with 160,800 tonnes at an average grade 7.42 g/t Au for 38,400 ounces in the Inferred category. The mineral resource does not include the results for holes drilled after November 2015, which represents 59,000 metres of drilling in 254 holes. On January 19, 2018, Monarch Gold Corporation announced the positive results of the pre-feasibility study prepared by InnovExplo Inc. The results of the pre-feasibility study show that the Croinor project is economically viable and has the potential to become a low-cost mine. Pre-feasibility study highlights: Pre-tax internal rate of return of 47.56%, net present value of $32 million.Cash production cost of $818/ounce (US$639/ounce) and total production cost of $1,155/ounce (US$902/ounce).Based on a gold price of US$1,280 and an exchange rate of 1.28 CAD/1 USD.The study does not include holes drilled after November 2015 (59,000 metres in 254 holes). The technical report summarizing the results of the pre-feasibility study can be viewed on Monarch's website. The Croinor Gold deposit is hosted in the Croinor Sill, a synvolcanic intrusion that has been traced along strike by drilling for over 2.4 km. Mineralization is hosted in quartz-carbonate-tourmaline-pyrite veins that can be traced from several tens of metres up to 600 metres. Table 3: Resources Estimate for the Croinor Gold deposit at the selected cut-off grades Cut-off g/tMeasured ResourcesIndicated ResourcesMeasured + Indicated ResourcesTonnesAu g/tOz AuTonnesAu g/tOz AuTonnesAu g/tOz Au> 5.0059,0009.8618,700538,00010.85187,600597,00010.75206,300> 4.0080,1008.4421,700724,5009.20214,300804,6009.12236,000> 3.00111,9007.0225,300997,5007.64244,9001,109,4007.57270,200 Notes: The Independent Qualified Persons for the Mineral Resource Estimate, as defined by NI 43-101, are Karine Brousseau, Eng., and Carl Pelletier, B.Sc., P.Geo. (InnovExplo Inc.); the effective date of the estimate is November 6, 2015.Mineral Resources, which are not Mineral Reserves, do not have demonstrated economic viability.The results are presented undiluted and in situ; the estimate includes 51 gold-bearing zones, some of which contain resources below the cut-off grade.The Mineral Resource was compiled at cut-off grades of 3, 4 and 5 g/t Au; however, the official resource is at a cut-off grade of 4 g/t.The cut-off grade should be reviewed in the light of prevailing market conditions (gold price, exchange rate and mining cost).A density of 2.8 g/cm3 was used for the mineralized zones and the waste rock.A minimum true thickness of 1.8 m was applied, using the grade of the adjacent material when assayed, or else a grade of zero.High-grade capping was applied to the raw assay data, and was established at 70 g/t Au for the diamond drill core and 55 g/t Au for the underground channel samples.Compositing was done on drill hole sections and underground channel sections falling within the mineralized zones (composite = 1 metre).Resources were estimated using GEOVIA GEMS 6.7 software from diamond drill holes and underground channel samples using an ID6 interpolation method in a block model (block size 5m x 2.5m x 2.5m).The Measured, Indicated and Inferred categories were defined using the parameters for the various passes.Isolated blocks in the Indicated category showing no spatial continuity in terms of grade and/or information density were reclassified from Indicated to Inferred.Blocks in the Inferred category showing good spatial continuity in terms of grade and/or information density were reclassified from Inferred to Indicated.Ounce (troy) = Metric Tons x Grade / 31.10348. Metric units (metres, tonnes and g/t) were used in the estimate.The tonnage estimate was rounded to the nearest hundred tonnes. Any discrepancies in the totals are due to the rounding effect; rounding followed the recommendations in Form 43-101F1. The technical and scientific content of this press release has been reviewed and approved by Louis Martin, P.Geo., the Corporation’s qualified person under National Instrument 43-101. About MonarchMonarch Mining Corporation (TSX: GBAR) is a fully integrated mining company that owns four advanced projects, including the fully permitted past-producing Beaufor Mine, which has produced more than 1 million ounces of gold over the last 30 years. Other advanced assets include the Croinor Gold, McKenzie Break and Swanson properties, all located near Monarch’s wholly owned and fully permitted 750 tpd Beacon mill. Monarch owns 28,725 hectares (287 km2) of mining assets in the prolific Abitibi mining camp that host 588,482 ounces of combined measured and indicated gold resources and 329,393 ounces of combined inferred resources. Forward-Looking Statements The forward-looking statements in this press release involve known and unknown risks, uncertainties and other factors that may cause Monarch’s actual results, performance and achievements to be materially different from the results, performance or achievements expressed or implied therein. Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this press release. FOR MORE INFORMATION: Jean-Marc Lacoste1-888-994-4465President and Chief Executive Officerjm.email@example.com Mathieu Séguin1-888-994-4465Vice President, Corporate Developmentm.firstname.lastname@example.org Elisabeth Tremblay1-888-994-4465Senior Geologist – Communications Specialiste.email@example.com www.monarchmining.com Table 4: Monarch combined gold resources Tonnes(metric) Grade (g/t Au)Ounces Croinor Gold1 Measured Resources80,1008.4421,700 Indicated Resources724,5009.20214,300 Total Measured and Indicated804,6009.12236,000 Total Inferred160,8007.4238,400 Beaufor mine2 Measured Resources121,0005.6221,900 Indicated Resources310,1007.1070,800 Total Measured and Indicated431,1006.6892,700 Total Inferred134,6006.9630,100 McKenzie Break3 In-pit Total Indicated1,441,3771.8083,305 Total Inferred2,243,5621.44104,038 Underground Total Indicated387,7205.0362,677 Total Inferred1,083,5034.21146,555 Swanson4 In-pit Total Indicated1,864,0001.76105,400 Total Inferred29,0002.462,300 Underground Total Indicated91,0002.868,400 Total Inferred87,0002.878,000 TOTAL COMBINED5Measured and Indicated ResourcesInferred Resources 588,482329,393 1 Source: Monarch Gold prefeasibility study (January 19, 2018) and resource estimate (January 8, 2016). This resource was completed for Monarch Gold and has not been reviewed by a qualified person for Monarch Mining as required under National Instrument 43-101 and is thus considered as an historical estimate. 2 Source: NI 43-101 Technical Report and Mineral Resource Estimate for the Beaufor Mine, December 18, 2020, Val-d’Or, Québec, Canada, Carl Pelletier, P. Geo., InnovExplo Inc. and John Langton, P. Geo., JPL GeoServices Inc.3 Source: NI 43-101 Technical Evaluation Report on the McKenzie Break Property, February 1, 2021, Val-d’Or, Québec, Canada, Alain-Jean Beauregard, P.Geo., Daniel Gaudreault, P.Eng., Geologica Groupe-Conseil Inc., and Merouane Rachidi, P.Geo., Claude Duplessis, P.Eng., GoldMinds GeoServices Inc.4 Source: NI 43-101 Technical Report and Mineral Resource Estimate for the Swanson Project, January 22, 2021, Val-d’Or, Québec, Canada, Christine Beausoleil, P. Geo. and Alain Carrier, P. Geo., InnovExplo Inc.5 Numbers may not add due to rounding.
Dublin, May 18, 2021 (GLOBE NEWSWIRE) -- The "Healthcare/Medical Simulation - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Healthcare/Medical Simulation Market to Reach $5.9 Billion by 2027Amid the COVID-19 crisis, the global market for Healthcare/Medical Simulation estimated at US$2.1 Billion in the year 2020, is projected to reach a revised size of US$5.9 Billion by 2027, growing at a CAGR of 15.9% over the analysis period 2020-2027. Healthcare Anatomical Models, one of the segments analyzed in the report, is projected to record a 17.2% CAGR and reach US$2.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Web-based Simulators segment is readjusted to a revised 16.1% CAGR for the next 7-year period.The U.S. Market is Estimated at $619.7 Million, While China is Forecast to Grow at 15.2% CAGRThe Healthcare/Medical Simulation market in the U.S. is estimated at US$619.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1 Billion by the year 2027 trailing a CAGR of 15.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.4% and 13.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 11.5% CAGR.Healthcare Simulation Software Segment to Record 15.4% CAGRIn the global Healthcare Simulation Software segment, USA, Canada, Japan, China and Europe will drive the 15.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$286.5 Million in the year 2020 will reach a projected size of US$770.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$701.9 Million by the year 2027.Key Topics Covered: I. METHODOLOGYII. EXECUTIVE SUMMARY1. MARKET OVERVIEW Influencer Market InsightsWorld Market TrajectoriesImpact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS(Total 35 Featured): 3D SystemsCAECardionics, Inc.Gaumard Scientific CompanyKyoto KagakuLaerdal MedicalLimbs & ThingsMedaphorMentice ABOperative Experience, Inc.Simulab CorporationSimulaidsSynBone AGVirtaMed AGVRMagic Holding AG 3. MARKET TRENDS & DRIVERS4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Healthcare/Medical Simulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Healthcare Anatomical Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Web-based Simulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Healthcare Simulation Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Simulation Training Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Military Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGRWorld Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR III. MARKET ANALYSIS IV. COMPETITION Total Companies Profiled: 35 For more information about this report visit https://www.researchandmarkets.com/r/dl972u CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Skit followed announcement that DeGeneres was ending her talk show after 19 years
A Spanish study on mixing COVID-19 vaccines has found that giving a dose of Pfizer's drug to people who already received a first shot of AstraZeneca vaccine is highly safe and effective, preliminary results showed on Tuesday. The Combivacs study, run by Spain's state-backed Carlos III Health Institute, found the presence of IgG antibodies in the bloodstream was between 30 and 40 times higher in people who got the follow-up Pfizer shot than in a control group who only received one AstraZeneca dose. Meanwhile, the presence of neutralising antibodies rose sevenfold after a Pfizer dose, significantly more than the doubling effect observed after a second AstraZeneca shot.
The duchess wore the T-shirt in the trailer for Prince Harry and Oprah Winfrey’s new docuseries
If you’re not getting all the sleep you need, it might be time to reconsider what you’re snoozing on
Indoor gigs are finally back on the cards. Here’s where to have a jolly good giggle
Conference Call on Tuesday, May 18, 2021 at 8:30 a.m. ETLEXINGTON, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Agenus executives will conduct a conference call to discuss the global licensing agreement between Agenus and Bristol Myers Squibb at 8:30 a.m. ET today. Conference CallDial-in numbers: (833) 614-1394 (US) or (914) 987-7115 (International); Conference ID: 6545558. WebcastA live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.agenusbio.com/events-and-presentations and via https://edge.media-server.com/mmc/p/gmikyrev. About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. The Company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. ContactAgenus Investor RelationsJan Medina, CFAAgenus781-674-4490Jan.Medina@agenusbio.com Agenus Media RelationsKimberly HaKKH Advisors917email@example.com
It will be the first time the contraptions will legally be allowed on the capital’s roads
National Academy of Arbitrators Appoints New Officers: Susan Stewart Succeeds Dan Nielsen as President; Homer LaRue Named President-Elect
OCALA, Fla., May 18, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the first quarter ended March 31, 2021. As of March 31, 2021, AIM had cash, cash equivalents and marketable securities of $63.6 million, compared to $54.4 million as of December 31, 2020. Research and development expenses for the three months ended March 31, 2021 were $1.4 million, compared to $0.9 million for the three months ended March 31, 2020. General and administrative expenses for the three months ended March 31, 2021 were $2.1 million, compared to $2.3 million for the three months ended March 31, 2020.The net loss from operations for the three months ended March 31, 2021 was $3.6 million, or $0.08 per share, compared to $3.8 million, or $0.22 per share, for the three months ended March 31, 2020. “I’m extremely proud of the progress we have made throughout the first quarter,” commented Thomas K. Equels, CEO of AIM ImmunoTech. “We have established a strong foundation of pre-clinical and clinical data with respect to the development of therapeutics aimed to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. With our solid financial standing, we intend to execute on our corporate strategy and aggressively move forward with our clinical programs that address critical unmet medical needs. We have reached many important milestones, are encouraged by the outlook for AIM and look forward to providing meaningful updates along the way.” Please refer to the full 10-Q for complete details. Additionally, please refer to AIM’s most recent Company Presentation for updates on ongoing clinical studies. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development oftherapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus. Investor Relations Contact:Crescendo Communications, LLCPhone: 212-671-1021Email: firstname.lastname@example.org AIM ImmunoTech IncPhone: 800-778-4042Email: IR@aimimmuno.com
70% of global T&L leaders agree that reducing downtime of mobile devices in the field is a top business concern for their organization.MISSISSAUGA, Ontario, May 18, 2021 (GLOBE NEWSWIRE) -- An increase in e-commerce sales of up to 27.6% in the last year is causing transportation and logistics (T&L) companies tremendous strain as they work to fulfill a surge in orders due to the global pandemic. To scale their businesses and deal with changing consumer and business behaviors, a new global research report by mobile and IoT management solutions provider, SOTI, found that 74% of T&L companies had already begun to invest in mobile technology, wearables and IoT solutions in 2020. A significant 80% plan to continue to invest in mobile technology throughout 2021. The Mobilizing the Delivery Workforce: State of Mobility in T&L 2021 Report interviewed 550 IT decision-makers in the T&L industry across eight countries (U.S., Canada, Mexico, UK, Germany, France, Sweden and Australia), to understand the trends and solutions that are driving their organizations and how the pandemic affected operations. Legacy Systems Not Integrated With New Investments Continue to Hinder Success and Result in Employees Losing Two Days of Work Per Month Due to Mobile Device Downtime Despite this widespread investment in technology from T&L companies in 2020 and 2021, SOTI’s research indicated that this investment was not delivering the desired outcomes, with respondents suggesting that a lack of integration with existing systems is limiting productivity, creating siloed workflows and ultimately causing workers to lose valuable time when out in the field. The delay due to mobile device downtime has led to 98% of global employees losing valuable work hours. Nearly one-third (32%) state that the main cause of downtime that cause shipping delays is the lack of IT support to address mobile device downtime issues, and self-serve applications that allow drivers to diagnose and troubleshoot device issues independently while they are on the road. On average, organizations are losing 3.3 hours per employee each work week dealing with technical or system difficulties (device downtime), with a global average of 14 hours lost per employee per month. Average Downtime Around the Globe Among T&L Companies (Per Employee): Canada17 hours per monthU.S.15 hours per monthUK15 hours per monthGermany15 hours per monthSweden15 hours per monthFrance12 hours per monthMexico11 hours per month “The pandemic put a spotlight on the need for an integrated technology strategy,” said Shash Anand, VP of Product Strategy, SOTI. “While we are seeing a clear investment in technology from T&L companies, we are not seeing a cohesive strategy for the implementation of new tech to counteract the repercussions of the pandemic. It is crucial for T&L decision-makers to understand that by not taking these factors into account, their organizations are wasting time and leaving money and productivity on the table.” Transportation and Logistics Companies Reliant on Pen and Paper Processes Making Errors Once investments have been made, an even bigger cause of employee downtime is the lack of integration with existing systems. This creates inefficiencies, often causing employees to rely on paper-based processes, causing further inefficiencies and room for manual errors. The following examples were more frequently cited: 45% say staff are updating multiple systems manually 31% say legacy tech is not fully integrated with new systems 29% say that information is not shared across all systems used When asked about the issues causing downtime and delaying shipments, T&L employees cited the following: Updated information is not automatically shared across all the systems used (28%)There is a lack of staff training on the usage of technology (26%) Systems are not upgraded frequently enough (24%) “There is a clear disconnect from the technology that T&L companies recognize they need, to the seamless adoption into their existing infrastructure,” continued Anand. “With an integrated mobility and IoT management platform, T&L companies are not only able to increase speed, but also minimize costs and ensure transparency in the delivery channel..” SOTI’s Mobilizing the Delivery Workforce: State of Mobility in T&L 2021 Report can be downloaded here. Report MethodologyCommissioned by SOTI, Arlington Research, an independent market research agency, conducted 550 interviews using an online methodology among IT Managers, IT Directors, Senior Management and C-Suite (all disciplines) working in the T&L vertical across eight countries. All respondents are aged 18 and over and work in companies with 50 or more global employees. Fieldwork was conducted March 18 to 30, 2021. The 550 interviews were split across eight markets as follows: U.S., Canada, Mexico, UK, Germany, France, Sweden and Australia. About SOTISOTI is the world’s most trusted provider of mobile and IoT management solutions, with more than 17,000 enterprise customers and millions of devices managed worldwide. SOTI’s innovative portfolio of solutions and services provide the tools organizations need to truly mobilize their operations and optimize their mobility investments. SOTI extends secure mobility management to provide an integrated solution to manage and secure all mobile devices and connected peripherals in an organization. For media enquiries, please contact:SOTI Media Relationspress@soti.net 1 (519) 998-1966
Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone paymentsNEW YORK and LEXINGTON, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Bristol-Myers Squibb Company (NYSE: BMY) and Agenus Inc. (NASDAQ: AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies this approach has shown significant potential in tumor models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are ineffective. Under the agreement, Bristol Myers Squibb will become solely responsible for the development and any subsequent commercialization of AGEN1777 and its related products worldwide. Agenus will receive a $200 million upfront payment and up to $1.36 billion in development, regulatory and commercial milestones in addition to tiered double-digit royalties on net product sales. Agenus will retain options to conduct clinical studies under the development plan, to conduct combination studies with certain other Agenus pipeline assets, and also, upon commercialization, to co-promote AGEN1777 in the US. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Agenus expects to file an Investigational New Drug (“IND”) application for the development of AGEN1777 with the U.S. Food and Drug Administration in the second quarter of 2021. Bristol Myers Squibb intends to advance the research and development of AGEN1777 in immuno-oncology (“I-O”) for high priority tumor indications including non-small cell lung cancer. “AGEN1777’s differentiated mechanism of action provides the potential for potent anti-tumor activity; catalyzing our clinical TIGIT strategy aimed at serving more patients with unmet needs in cancer,” said Debbie Law, D.Phil., Senior Vice President, Head of Tumor Microenvironment Thematic Research Center, Bristol Myers Squibb. “We look forward to working with Agenus to develop this important therapy as we continue to combat I-O resistance.” “We are pleased to partner with Bristol Myers Squibb to develop and commercialize AGEN1777. Their stellar record of success in this area has been an important determinant for our decision to enter into this transaction,” said Garo Armen, PhD, Chairman and Chief Executive Officer of Agenus. “Through such transactions we are able to balance between advancing our portfolio with highly qualified collaborators, while retaining our other innovations for speedy development and commercialization by Agenus.” About AGEN1777 AGEN1777 is a potentially first-in-class bispecific anti-TIGIT antibody engineered with an enhanced Fc region for high binding affinity and improved T and NK cell activation. About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body’s immune system to fight cancer. The Company’s vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter. Agenus Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding clinical development and regulatory plans and timelines related to AGEN1777 and other programs, potential receipt of development, regulatory and commercial milestones and the potential clinical benefit of such programs. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram. Bristol Myers Squibb Cautionary Statement Regarding Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products and the license agreement. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that the expected benefits of, and opportunities related to, the license agreement may not be realized by Bristol Myers Squibb or may take longer to realize than anticipated and that Bristol Myers Squibb may fail to discover and develop any commercially successful product candidates through the license agreement. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2020, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. Contacts Bristol Myers Squibb Media:email@example.comInvestors:Tim Power, 609-252-7509, firstname.lastname@example.orgNina Goworek, 908-673-9711, email@example.com Agenus Media:Kimberly Ha, KKH Advisors, 917-291-5744, firstname.lastname@example.org Investors:Jan Medina, CFA, Agenus, 781-674-4490, Jan.Medina@agenusbio.com
Values Midtown South Property Over $1,200 per square footNEW YORK, May 18, 2021 (GLOBE NEWSWIRE) -- SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, today announced the sale of 635-641 Sixth Avenue for a gross sales price of $325.0 million. The property is comprised of two adjoined buildings totaling 8 stories and 267,000 square feet, occupying the full western block-front on Sixth Avenue from 19th Street to 20th Street in Midtown South. The transaction is expected to close in the second quarter of 2021, subject to customary closing conditions, and generate net cash proceeds to SL Green of approximately $312.5 million. “New York City’s revitalization continues as does the demand for Class A office buildings,” said Harrison Sitomer, Senior Vice President. “The disposition at a sale price of more than $1,200 per square foot is a result of extensive repositioning and leasing efforts at the property, which is further evidence of the breadth of expertise that the SL Green platform brings to the table. Completion of this transaction represents another step in the successful execution of our 2021 business plan.” The property is currently 94% leased and anchored by multi-national enterprise software company, Infor, through 2030, following a recently executed renewal and extension. SL Green acquired the Property in 2012 for $173.0 million and completed its redevelopment in 2015, including a new lobby, elevators, state-of-the-art building systems and a one-of-a-kind penthouse rooftop that includes outdoor amenity and event space. Darcy Stacom, William Shanahan and Doug Middleton of CBRE represented SL Green in the transaction. About SL Green Realty Corp. SL Green Realty Corp., Manhattan’s largest office landlord, is a fully integrated real estate investment trust, or REIT, that is focused primarily on acquiring, managing and maximizing value of Manhattan commercial properties. As of March 31, 2021, SL Green held interests in 84 buildings totaling 37.8 million square feet. This included ownership interests in 28.3 million square feet of Manhattan buildings and 8.7 million square feet securing debt and preferred equity investments. Forward Looking Statement This press release includes certain statements that may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are intended to be covered by the safe harbor provisions thereof. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future, are forward-looking statements. Forward-looking statements are not guarantees of future performance and actual results or developments may differ materially, and we caution you not to place undue reliance on such statements. Forward-looking statements are generally identifiable by the use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “continue,” or the negative of these words, or other similar words or terms. Forward-looking statements contained in this press release are subject to a number of risks and uncertainties, many of which are beyond our control, that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by forward-looking statements made by us. Factors and risks to our business that could cause actual results to differ from those contained in the forward-looking statements include risks and uncertainties related to the on-going COVID-19 pandemic and the duration and impact it will have on our business and the industry as a whole and the other risks and uncertainties described in our filings with the Securities and Exchange Commission. Except to the extent required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information or otherwise. SLG - A&D Matt DiLibertoChief Financial Officer212.594.2700